Ernexa Therapeutics Inc. ERNA
Set alert
1.97 USD -0.14 -6.64%
At close · Oct 30
2.30 +0.33 +16.75%
After hours · Oct 30, 4:00 PM ET
1.97 Day range 2.14
1.94 52-week range 47.00
- YTD
- -93.43%
- 1 year
- -95.57%
- Open
- 2.14
- Prev close
- 2.11
- Mkt cap
- 3.22M
- Vol
- 4.49K
- Avg vol
- 50.65K
- EPS
- -13.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.97
- High
- 2.14
- Forward P/E
- -0.03
- Beta
- 7.77
- Short ratio
- 1.07
- Inst. own
- 11.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.7302
- 200-d avg
- 1.58
- 1y target
- 0.00
Key statistics
- Market cap
- 12.61M
- Enterprise value
- 51.71M
- Trailing P/E
- 0.00
- Forward P/E
- -0.03
- PEG ratio
- 0.00
- Price / sales
- 77.82
- Price / book
- 0.59
- EPS (TTM)
- -8.31
- Beta
- 7.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 162.00K
- Revenue growth
- 0.00%
- Free cash flow
- -11.78M
- Total cash
- 2.59M
- Total debt
- 49.20M
- Return on equity
- 0.00%
- Shares outstanding
- 51.37M
- Short % of float
- 0.09%
- 50-day average
- 0.7302
- 200-day average
- 1.58
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ERNA Revenue — quarterly 0
ERNA Net income — quarterly -4.01M
ERNA EPS — quarterly -3.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -4.92 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -1.02 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.23 | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | -1.14 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -1.03 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -0.85 | — | — |
About Ernexa Therapeutics Inc.
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eternatx.com
News
- Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
- Ernexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8
- Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
- Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine
- Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on ERNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 28, 2024 | 16,628,100 |
| GURROLA SANDRA M | Officer | Conversion of Exercise of derivative security | Jun 20, 2024 | 1,185 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Corient Private Wealth LLC | 0.51% | 262,862 | 64.51K | Sep 29, 2024 |
| Cypress Point Wealth Management, LLC | 0.18% | 94,375 | 23.16K | Sep 29, 2024 |
| UBS Group AG | 0.16% | 83,620 | 20.52K | Sep 29, 2024 |
| Naviter Wealth, LLC | 0.15% | 78,796 | 19.34K | Sep 29, 2024 |
| Sippican Capital Advisors | 0.13% | 68,504 | 16.81K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.06% | 32,860 | 8.06K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.05% | 26,099 | 6.40K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.03% | 13,097 | 3.21K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 3,129 | 767 | Oct 30, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 8 | 1 | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 2,047 | 502 | Oct 30, 2024 |